Cargando…
Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
BACKGROUND: Renal cell carcinoma (RCC) is a common malignancy with approximately 30% of cases diagnosed at the advanced or metastatic stage. While single-agent vascular endothelial growth factor-targeted therapy has been a mainstay of treatment, data from multiple phase III trials assessing first-li...
Autores principales: | Lalani, Aly-Khan A., Heng, Daniel Y. C., Basappa, Naveen S., Wood, Lori, Iqbal, Nayyer, McLeod, Deanna, Soulières, Denis, Kollmannsberger, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244935/ https://www.ncbi.nlm.nih.gov/pubmed/35782749 http://dx.doi.org/10.1177/17588359221108685 |
Ejemplares similares
-
Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System
por: Cardenas, Luisa M., et al.
Publicado: (2023) -
Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma
por: Parmar, Ambica, et al.
Publicado: (2022) -
Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System
por: Nguyen, Eric K., et al.
Publicado: (2022) -
The Rapidly Evolving Landscape of First‐Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review
por: Lavoie, Jean‐Michel, et al.
Publicado: (2021) -
Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts
por: Bossé, Dominick, et al.
Publicado: (2020)